Kaituo Pharmaceuticals-B (09939.HK) achieved sales revenue exceeding the total of last year, reaching 34 million yuan in 2026, with a target of 150 million yuan for the full year.

Gelonghui, April 20th - Kaituo Pharmaceuticals-B (09939.HK) announced that since the beginning of 2026, the company's B2C and B2B sales businesses have experienced rapid and stable growth. According to the company’s preliminary statistics, as of the date of this announcement, the cumulative revenue achieved in the current year has already surpassed the total revenue for the entire year of 2025. As of the date of this announcement, the company’s revenue for the current year has reached approximately RMB 34 million, exceeding last year’s total revenue of RMB 32.68 million. The company is on track to achieve the annual target of surpassing RMB 150 million, with the main contributing components including domestic e-commerce sales under the B2C segment.

Gelonghui FinanceApr 20 21:23

The National Healthcare Security Administration will focus on optimizing the centralized procurement rules and strengthening the implementation of outcomes, among other measures.

Deputy Director of the National Healthcare Security Administration, Shi Zihai, stated that since 2018, the national level has carried out 11 rounds of centralized bulk procurement for medicines, covering 490 types of drugs. Moving forward, the authorities will focus on improving the price formation mechanism for drug procurement based on the recently announced 'Several Opinions on Improving the Drug Price Formation Mechanism.' He mentioned that procurement rules will be optimized according to the characteristics of different types of drugs, and efforts will be made to ensure the effective implementation of selected procurement results. For instance, other non-selected products, including originator drugs, can be used to avoid a 'one-size-fits-all' approach in clinical selection. Additionally, the authorities will enhance guidance for local procurement initiatives and strengthen coordination.

AASTOCKSApr 15 11:56

The Ministry of Industry and Information Technology (MIIT) is currently drafting the pharmaceutical industry's 15th Five-Year Development Plan, aiming to accelerate the availability of high-quality and fairly-priced medicines in the market.

He Yaqiong, Director of the Department of Consumer Goods Industry at the Ministry of Industry and Information Technology, stated at a regular policy briefing of the State Council that the ministry is currently drafting the "15th Five-Year Development Plan for the Pharmaceutical Industry." The next step will focus on achieving "four accelerations," including the development of an "innovative pharmaceuticals sector," "inclusive pharmaceuticals sector," "digitally intelligent pharmaceuticals sector," and "open pharmaceuticals sector." He Yaqiong emphasized that improving quality and reducing prices are not a zero-sum game. He encouraged research and development institutions as well as manufacturing enterprises to strive for high sales volumes at lower profit margins, seize opportunities in industrial development, accelerate the integration of artificial intelligence technologies, and strike a balance among quality, price, and accessibility. This would promote the early market availability of more high-quality ye

AASTOCKSApr 15 11:30

Hong Kong Stock Movement | Kaituo Pharmaceuticals-B (09939) surged nearly 14% in the afternoon session, with annual revenue increasing more than fivefold year-on-year; cosmetic business funds core product R&D.

Kaituo Pharmaceuticals-B (09939) surged nearly 14% in the afternoon trading session. As of the time of writing, it was up 10.45%, trading at HKD 2.96, with a turnover of HKD 14.1222 million.

Zhitong FinanceApr 10 14:19

Trump takes action on pharmaceuticals! Import drugs face a maximum tax rate of 100%.

Trump fulfilled his threat by imposing a tariff of up to 100% on certain imported patented drugs. However, giants such as Merck and Eli Lilly and Co had already privately 'negotiated for exemptions.' Who will ultimately bear the brunt?

Golden10 DataApr 3 07:59

Kaituo Pharmaceuticals-B declined, with annual losses widening to 200 million yuan, due to impairment losses on intangible assets following the suspension of non-dermatology pipelines.

Kaituo Pharmaceuticals-B (09939) plunged over 10%, with its share price having cumulatively dropped more than 40% over the past nine trading sessions.

Zhitong FinanceMar 31 11:10